The sequencing-based, laboratory-developed test, called SmartJane, contains the first commercially available vaginal microbiome assay.

The collaborators plan to collect samples that will allow them insight into participants' microbiomes in order to understand disease mechanisms over time.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.